SCHEMBL4361761

SCHEMBL4361761

c1ccc(-c2cncc(-c3nc4ccccc4cc3-c3ccccc3)c2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PSMB5 P28074 1/20 0.50
▸ AKT1 P31749 1/20 0.50
▸ PDE10A Q9Y233 1/20 0.47
▸ ALDH1A1 P00352 3/20 0.44
▸ KDM4E B2RXH2 3/20 0.44
▸ L3MBTL1 Q9Y468 2/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ CYP2A6 P11509 1/20 0.44
▸ NPC1 O15118 3/20 0.42
▸ RAB9A P51151 3/20 0.42
▸ PDGFRB P09619 1/20 0.42
▸ PDGFRA P16234 1/20 0.42
▸ CYP11B1 P15538 2/20 0.41
▸ CYP11B2 P19099 1/20 0.41
▸ MKNK1 Q9BUB5 1/20 0.41
▸ MKNK2 Q9HBH9 1/20 0.41
▸ MEN1 O00255 4/20 0.40
▸ KMT2A Q03164 4/20 0.40
▸ MAPT P10636 2/20 0.39
▸ GLA P06280 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4361764 0.94 PDE10A (0.51) PSMB5AKT1PDE10AALDH1A1KDM4E
SCHEMBL3359420 0.84 PSMB5 (0.65) PSMB5AKT1PDE10AALDH1A1KDM4E
SCHEMBL29374375 0.84 PSMB5 (0.65) PSMB5AKT1PDE10AALDH1A1KDM4E
Ammonia Solution, Strong SCHEMBL28129677 0.83 PSMB5 (0.63) PSMB5AKT1PDE10AALDH1A1KDM4E
SCHEMBL31054483 0.83 PSMB5 (0.63) PSMB5AKT1PDE10AALDH1A1KDM4E
SCHEMBL28284780 0.81 CYP2A6 (0.56) PSMB5AKT1PDE10AALDH1A1KDM4E
SCHEMBL27656250 0.81 CYP11B1 (0.57) PSMB5AKT1PDE10AALDH1A1KDM4E
SCHEMBL28846224 0.80 PSMB5 (0.56) PSMB5AKT1PDE10AALDH1A1KDM4E
SCHEMBL22673549 0.79 CYP11B2 (0.61) PSMB5AKT1ALDH1A1KDM4ECYP2A6
SCHEMBL29892034 0.78 PDGFRB (0.50) PSMB5AKT1PDE10AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482456-B2 antiasthmatic; antiinflammatory; minimal side effects; 8-(3-{2-(3-chlorophenyl)-4-[4-(methylsulfonyl)phenyl]-1,3-thiazol-5-yl}phenyl)-6-[1-methyl-1-(methylsulfonyl)ethyl]quinoline; 2-[5-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-4-pyridin-3-yl-1,3-thiazol-2-yl]propan-2-ol MERCK FROSST CANADA 2009-01-27 — — US disclosed
US-20060223850-A1 8-(3-Biaryl)phenylquinoline phosphodiesterase-4 inhibitors MERCK FROSST CANADA & CO. (CA) 2006-10-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223850-A1 8-(3-Biaryl)phenylquinoline phosphodiesterase-4 inhibitors PDE4A, PDE4B, PDE3B PSMB5 2238/4885AKT1 1138/4885PDE10A 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback